Pfizer
-
President Joe Biden paid Michigan a visit and toured a Pfizer factory, where he begged Americans to take the vaccine when it’s their turn.
-
Federal authorities are investigating after some COVID-19 vaccine recipients have developed the rare blood disorder thrombocytopenia.
-
Pfizer expects total revenue in sales of CCP virus vaccines it has developed with Germany’s BioNTech to generate roughly $15 billion in 2021. The New York ...
-
The UK COVID-19 death toll surpassed 100,000. UK Prime Minister Boris Johnson says he is deeply sorry for every life lost and takes full responsibility. The ...
-
Pfizer on Friday committed to supply up to 40 million doses of its COVID-19 vaccine this year to a World Health Organization-backed effort to get affordable ...
-
Questions arising about the safety of the new Pfizer vaccine. Some elderly people are reportedly dying hours or days after taking the vaccine. The highly anticipated ...
-
Thousands of people have been unable to work or perform daily activities, or required care from a healthcare professional, after getting the new COVID-19 vaccine, according ...
-
NEW YORK—The U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE’s COVID-19 vaccine ...
-
Vice President Mike Pence will be injected with the newly approved COVID-19 vaccine in an event on Friday, while Joe Biden plans to get vaccinated soon.
-
Two health workers in Alaska suffered allergic reactions, one of which was serious, after receiving the COVID-19 vaccine made by Pfizer and BioNTech.
-
The Food and Drug Administration is finalizing its approval of the Pfizer-BioNTech COVID-19 vaccine
-
WASHINGTON—A 23-member vaccine advisory panel voted on Dec. 10 to support the emergency use authorization (EUA) of the COVID-19 vaccine created by Pfizer-BioNTech. The final decision ...
-
U.S. stocks are slipping Wednesday and pulling back from their recent record highs as virus cases surge and coronavirus vaccines move closer to distribution. A vaccine ...
-
The Pfizer/BioNTech vaccine is the first to be approved by the UK regulator and will be available for use in the UK within days, the government ...
-
In Phase 3 of clinical trials, Pfizer said it found that it’s vaccine, known as BNT162b2, was 95 percent effective in developing an immunity to COVID-19.
-
Pfizer has filed for emergency use authorization of its COVID-19 vaccine on Friday
-
One of the leading COVID-19 vaccine candidates was 94 percent effective in adults older than 65, according to new clinical trial results.
-
Pfizer Inc has launched a pilot delivery program for its experimental COVID-19 vaccine in four U.S. states, as the U.S. drugmaker seeks to address distribution challenges ...
-
On Monday, Pfizer and its German partner Bio-N-Tech announced that it had preliminary results for a vaccine that’s more than 90 percent effective. It sounds like ...
-
Pfizer's CEO sold shares worth $5.6 million the day the drugmaker announced that its CCP virus vaccine was more than 90 percent effective.
-
1. UK hospital: 600 staff off due to COVID-19 2. Germans skeptical about Pfizer’s COVID vaccine 3. Two Belarusian diplomats expelled from UK 4. Denmark mink ...
-
A COVID-19 vaccine candidate proved strongly effective in a large phase 3 study, according to results released on Nov. 9.
-
The US presidential election is having an impact on Chinese stocks. It spells both good and bad news for the communist regime.
-
Pfizer Inc received informal requests relating to its operations in China from the U.S. Department of Justice and the U.S. Securities and Exchange Commission
-
President Donald Trump is set to deliver remarks and sign a series of executive orders on lowering drug prices at 3.00 pm EDT (1900 GMT) on Friday, ...
-
WASHINGTON—The Trump administration will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing, ...
-
Pfizer to Buy Array BioPharma in Deal Worth $11.4 Billion
MOST VIEWED STORIES